Ulixertinib hydrochloride

盐酸乌利塞替尼

AC-35822 | Ulixertinib (hydrochloride) | Ulixertinib hydrochloride | 1956366-10-1 | 1H-Pyrrole-2-carboxamide, 4-(5-chloro-2-((1-methylethyl)amino)-4-pyridinyl)-N-((1S)-1-(3-chlorophenyl)-2-hydroxyethyl)-, hydrochloride (1:1) | UNII-3K792HRQ8B | 3K792HRQ8B

Ulixertinib hydrochloride

U649751-5mg

5mg

≥99%

2-8°C储存,干燥

冰袋运输

Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC 50 of In Vitro Combined Ulixertinib (BVD-523; 10, 20, 30 μM; 48 hours) and VS-5584 treatment causes significant induction of cell death in human pancreatic cancer (HPAC) cells in PDAC cell lines BxPC-3, MIAPaCa-2, and CFPAC-1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid

盐酸乌利昔替尼（BVD-523 盐酸盐）是一种强效、口服活性、高选择性、ATP 竞争性和可逆的 ERK1/2 激酶共价抑制剂，对 ERK2 的 IC 50 小于 0.3 nM。盐酸乌利克替尼可抑制ERK1/2激酶的磷酸化。

1956366-10-1

C21H23Cl3N4O2

469.8 g/mol

71584481

CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl.Cl

N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1H-pyrrole-2-carboxamide;hydrochloride

1S/C21H22Cl2N4O2.ClH/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13;/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29);1H/t19-;/m1./s1

DKGYQCPFBWFTHM-FSRHSHDFSA-N

CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)Cl.Cl

71584481

1956366-10-1

DMSO : 100 mg/mL (212.86 mM; Need ultrasonic) H2O : 0.1 mg/mL (0.21 mM; ultrasonic and warming and heat to 80°C)

5

4

7

468.089 Da

468.089 Da

90.000 Ų

30

0

539.000

0

2